#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15326	16S	1529	1529	99.87	16S.l15.c17.ctg.2	2395	770.1	0	.	n	.	0	A69G	SNP	69	69	A	336	336	G	952	G,A,C	710,239,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15326	16S	1529	1529	99.87	16S.l15.c17.ctg.2	2395	770.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1717	1717	T	952	T,G,C,A	944,4,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15326	16S	1529	1529	99.87	16S.l15.c17.ctg.2	2395	770.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1451	1451	C	962	C,A,T	960,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25790	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3908	821.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1854	1854	A	1054	A,G	1053,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25790	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3908	821.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2488	2488	C	891	C,T,G	888,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25790	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3908	821.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2562	2562	A	842	A,C	841,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25790	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3908	821.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3114	3114	C	906	C,A,G,T	901,1,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	16	8	blaTEM	861	263	100.0	blaTEM.l15.c4.ctg.1	263	1.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_U_01433c	folP.WHO_U_01433c	1	1	539	2210	folP	852	852	99.88	folP.l15.c17.ctg.1	1958	140.4	0	.	p	.	0	E151K	NONSYN	451	453	GAA	986	988	AAA	229;227;228	A;A;A,C	229;227;227,1	.	.
folP.WHO_U_01433c	folP.WHO_U_01433c	1	1	539	2210	folP	852	852	99.88	folP.l15.c17.ctg.1	1958	140.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1217	1219	AGC	246;247;248	A;G;C	246;247;248	folP.WHO_U_01433c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5418	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3985	169.8	1	SNP	p	S91F	0	.	.	271	273	TCC	886	888	TCC	199;198;198	T;C,A;C,A	199;197,1;197,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5418	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3985	169.8	1	SNP	p	D95N	0	.	.	283	285	GAC	898	900	GAC	197;198;204	G;A;C	197;198;204	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5418	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3985	169.8	1	SNP	p	D95G	0	.	.	283	285	GAC	898	900	GAC	197;198;204	G;A;C	197;198;204	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	2104	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1993	131.8	1	SNP	p	G45D	0	.	.	133	135	GGC	789	791	GGC	247;246;247	G;G;C	247;246;247	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1142	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1550	91.8	0	.	n	.	0	A197.	DEL	197	197	A	905	905	A	221	A	221	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4998	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3712	168.2	1	SNP	p	D86N	0	.	.	256	258	GAC	957	959	GAC	217;219;219	G;A,G,C;C	217;217,1,1;219	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4998	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3712	168.2	1	SNP	p	S87W	0	.	.	259	261	AGT	960	962	AGT	219;215;216	A;G;T	219;215;216	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4998	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3712	168.2	1	SNP	p	S87I	0	.	.	259	261	AGT	960	962	AGT	219;215;216	A;G;T	219;215;216	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4998	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3712	168.2	1	SNP	p	S87R	0	.	.	259	261	AGT	960	962	AGT	219;215;216	A;G;T	219;215;216	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4998	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3712	168.2	1	SNP	p	S88P	0	.	.	262	264	TCC	963	965	TCC	217;215;212	T,G;C;C,G	216,1;215;211,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4392	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3381	162.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1928	1930	GGC	246;246;245	G;G;C,A	246;246;244,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1542	1544	GCA	208;208;209	G;C;A,T	208;208;208,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1545	1547	ATC	207;207;207	A;T;CAAA,CAA	207;207;198,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1557	1559	GTG	204;205;204	G;T;G	204;205;204	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1557	1559	GTG	204;205;204	G;T;G	204;205;204	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2061	2063	ACC	237;239;239	A;C;C	237;239;239	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2115	2117	GCG	218;216;217	G,A,T;C;G	216,1,1;216;217	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2115	2117	GCG	218;216;217	G,A,T;C;G	216,1,1;216;217	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2238	2240	GGC	214;211;219	G;G,T;C	214;210,1;219	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2247	2249	GGC	218;218;219	G,C;G,C;C,T	217,1;217,1;217,2	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4040	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2990	168.6	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2265	2267	CTG	231;225;225	C;T;G,A	231;225;223,2	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5878	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3563	205.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1813	1815	CCG	248;249;247	C;C,A;G	248;248,1;247	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2518	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2431	129.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	895	895	C	203	C	203	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	26;27;27	T;T;A	26;27;27	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	60;60;60	C;A;T	60;60;60	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	60;60;60	A;G;T	60;60;60	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	60;60;60	T;A;C	60;60;60	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;3	G;A;C	2;2;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	3;3;3	A;G;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	302	27.2	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	100	95.0	porB1a.l15.c17.ctg.4	175	50.5	0	.	p	.	0	M18T	NONSYN	52	54	ATG	126	128	ACG	61;60;57	A,G,C;C,G;G	59,1,1;59,1;57	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	292	porB1a	984	100	95.0	porB1a.l15.c17.ctg.4	175	50.5	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	168	170	CAA	21;18;14	C;A;A	21;18;14	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3024	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1833	202.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	529	531	GAA	251;252;253	G,T;A;A	250,1;252;253	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3024	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1833	202.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	817	819	GAT	215;219;220	G;A;T	215;219;220	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3024	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1833	202.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	940	942	TCA	269;266;273	T;C,A;A	269;265,1;273	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3024	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1833	202.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1069	1071	GTC	231;232;237	G;T;C,T	231;232;236,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3024	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1833	202.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1399	1401	GCA	255;258;261	G;C;A,C	255;258;260,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3024	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1833	202.2	1	SNP	p	G120K	1	.	.	358	360	AAG	775	777	AAG	209;211;210	A;A;G	209;211;210	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3024	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1833	202.2	1	SNP	p	A121D	1	.	.	361	363	GAC	778	780	GAC	211;212;214	G;A;C	211;212;214	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3024	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1833	202.2	1	SNP	p	D121N	0	.	.	361	363	GAC	778	780	GAC	211;212;214	G;A;C	211;212;214	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9886	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5324	231.6	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2290	2292	AAT	236;234;236	A;A,C;T,G	236;233,1;235,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1398	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1611	108.0	1	SNP	p	V57M	1	.	.	169	171	ATG	746	748	ATG	241;243;241	A;T,C;G,T	241;242,1;240,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
